Skip to content
2000
Volume 19, Issue 23
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Alkylating agents such as temozolomide (TMZ) are effective anticancer drugs for treating a variety of solid tumors including melanoma, glioma, and astrocytoma. TMZ exerts its effects mainly via the mutagenic product O6-methylguanine, a cytotoxic DNA lesion. This damage may be repaired by the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT), a key player in the resistance of cancers to TMZ. Several strategies are presently being pursued to improve the killing of tumor cells by TMZ, with inhibition of MGMT being the most promising. In this review, we provide an overview of recent advances in this field.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986712802002446
2012-08-01
2025-10-31
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986712802002446
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test